AMOEBA (EPA:ALMIB) - AMOEBA: Ordinary and Extraordinary Annual General Meeting to be held on 13th March 2020 / Modalities through which the preparatory documents will be made available

Transparency directive : regulatory news

24/02/2020 17:45

PRESS RELEASE
Chassieu, 24 february 2020

ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON 13th march 2020
   MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

The General Meeting of Amoéba shareholders, convened on January 30, 2020 at 10
a.m. at the Company's registered office, did not reach the quorum required to
vote on the ordinary and extraordinary resolutions.

Consequently, a new Ordinary and Extraordinary Shareholders' Meeting will be
held on second call on:

                        Friday 13th march 2020 - 10 am
     at the company registered office - 38 Avenue des Frères Montgolfier -
                                69680 CHASSIEU

for the purpose of ruling on the same agenda, published in the Bulletin des
Annonces Légales Obligatoires (BALO) of 15 January 2020.

The notice of the second convocation including the agenda was published in the
Bulletin des Annonces légales Obligatoires (BALO) of February 12, 2020. The
terms and conditions of participation and voting at the Meeting are set out in
this notice.

The documents stipulated by article R.225-83 of the French commercial code are
available to shareholders from the moment that the assembly is convened, in
line with the applicable regulatory requirements:

* Any named shareholder can, until the fifth day (inclusive) before the
  assembly, ask the company to send them these documents. For holders of bearer
  shares, this right can only be exercised upon presentation of a statement of
  participation in the accounts of bearer shares held by the authorised
  intermediary;

* Any shareholder can consult these documents at the company's headquarters
  during the 15 days preceding the date of the assembly.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
     MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
     Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors Relations
Grégory BOSSON
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Medias relations
Constance LOZET
Agence Ekno
+33(0)7 78 41 19 70
constance.lozet@ekno.fr

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA: Ordinary and Extraordinary Annual General Meeting to be held on 13th March 2020 / Modalities through which the preparatory documents will be made available

Transparency directive : regulatory news

AMOEBA's latest news

Other stories